

Formulation and Evaluation of Cetuximab as buccal dissolving lollipop for treating gums cancer

Abdallah Mohamed Ahmed Mohamed*

Submitted: 01-03-2023

Accepted: 12-03-2023

ABSTRACT: Gums are a component of the soft tissue lining of the mouth. The gums seal off the tooth base by encircling it. Anatomically, the gums are separated into interdental, attached, and marginal portions. Gingival margins, the margin of the gums that form a collar-like covering around the teeth is known as the marginal gum, gum affixed, the marginal gum is continuous with the linked gums, gum between teeth is the interdental gum. human run a higher risk if he uses tobacco in any form—cigars, chewing tobacco, pipes, etc. Another risk factor is heavy alcohol consumption. Additionally, mouth cancer is more likely to strike those who have the human papillomavirus, or HPV. In rare cases, cetuximab, a novel medication known as a targeted therapy, is used to treat oral cancer instead of conventional chemotherapy. The flavor-enhanced dosage forms of the medicated lollipops are designed to be sucked and held in the mouth or pharynx. These formulations are frequently employed to achieve either local or systemic effects, loading a cetuximab drug on lollipop as buccal dissolving formulations may be more convenient for those patients affected by gums cancer instead of injection to achieve systemic and local therapeutic, in this review article we keep a look behind the formulation and evaluation of cetuximab as buccal dissolving lollipop for treating gums cancer in human.

Key words: Cetuximab, Medicated lollipop, Gums cancer, human papillomavirus, buccal dissolving lollipop

I. INTRODUCTION.

An angle of a teeth's crown wherever it contacts their foundations at the gum line are referred to a gum points degrees, commonly known as the gum endpoint of axial line angles, which, with term gingival added, are known as that of the axis line angles[1]. The disto-labio-lingual, disto-linguo-lingual, mesio-labio-lingual, and mesio-linguo-lingual angles can be found in the cuspids and incisors. Angles on the buccal are referred to by the same terms as those on the adult teeth and molar, and that therefore oral is used in replace of labial[2]. These are the mesio-bucco-lingual angle

and the disto-bucco-lingual angle, respectively. Since they haven't yet been used in descriptions of teeth, the gum point angles are just included here for completeness' sake. These are merely presented here for completeness' sake. those British When the various surfaces of a tooth are considered, each is considered to have individual edges & angles or to be a part of another surface. This name of the surface it meets serves as the identifier for each margin, with the exception of the gingival margin, which extends towards the gingival line. Bicuspid or molars teeth have the gum, mesial, terminal, and occlusal borders on their buccal surface. On an incisor's labial surface, there are incisal, mesial, distal, and gingival borders. The names of the borders of the buccal and labial surfaces of all teeth are identical to those of the lingual surfaces. Also, the names of the distal and mesial surface borders are the same. The gingival, buccal, lingual, and occlusal edges make up the mesial or terminal surface of a bicuspid or molar. Only three edges—the gingival, labial, and lingual—can be found on the mesial and distal surfaces of the incisors and cuspids due to their triangular structure. The mouth cavity is home to up to 1000 different kinds of microorganisms, such as different types of bacteria, fungi, virus, archaea, and protozoan species[3]. In a complex microenvironment, these creatures survive and flourish. The oral microbiota, a special kind of microbiome, is produced by the intricate interactions between each of the bacteria. It's interesting to notice that the oral microbiota and human host cells cohabit without conflict in the oral cavity. The oral bacteria and innate immune interactions that take place in the human buccal mucosa are now referred to as the "oralome" as a result. In this context, eubiosis refers to the healthy symbiotic relationships between the host's microbiome and these bacteria. The microbial composition is greatly influenced by interactions between species and between microbes and their hosts. The microbial changes may affect the host's health and illness state since eubiosis is essential for the development both of the patient's natural oral physiology and its defence mechanisms. Even though the oral bacteria can frequently counteract



larger-scale disturbances, some changes can have a major effect on its composition, changing the groups of oral commensals and resulting in the dysbiosis, a state in which the microbiome is out of balance. External and/or internal microbial-ecological changes to the oral microbiome can lead to dysbiosis, a condition in which the microbiome is out of balance. It has been said that this specific ailment has the ability to disseminate illness throughout the host. The oral microbiome has undergone a dysbiotic shift, which is the most widely accepted idea for how periodontitis begins and progresses. This is because periodontitis is regarded to be an inflammatory disorder that is initiated by pathogenic bacteria. This change is being driven by an increase in the abundance of *Bacteroides intermedia*, *Fusobacterium nucleatum*, *Porphyromonas mucosa*, *Tonnarelli forsythia*, & *Trypanosoma denticule* species in the microbiome. A gut microbial dental biofilm specifically enters the gum pocket and activates the host immune system. In response, the gingival tissue becomes inflamed (gingivitis), which eventually leads to tissue loss and periodontitis. Oral dysbiosis has been connected to many systemic diseases and conditions, including Alzheimer's disease, diabetes, adverse pregnancy outcomes, and a variety of malignancies, including stomach, lungs, abdomen, prostate, and uterine cancer. The objective of this study is to evaluate the epidemiological evidence linking gum disease to these cancer types, provide insights into the mechanisms through which diverse microbial dysbiosis can cause these diseases, and evaluate the growing body of evidence supporting the use of microbiota & related substances (such as bacteria) for prevention and treatment of cancer. For more details on the interactions between oral presenter and the effects of oral dysbiosis on different systemic diseases. Oral squamous cell carcinoma (OSCC), which makes up 2.3 percent of all malignancies in people, is the sixth most prevalent type of cancer in the world. A dismal prognosis and disease-related death are present in more than 50% of OSCC patients identified each year. Nowadays, surgery is used to manage and treat the bulk of OSCC patients, and concomitant chemoradiotherapy after surgery is the accepted gold standard of treatment for increased OSCC. As a result of this therapeutic strategy, locoregional control & disease-free survival have increased dramatically, but overall survival has also not (OS). Although the reasons for the lack of OS development are yet understood, distant metastasis has just been suggested as a risk

factor (DM). In the head and neck region, the oral cavity (3.2%) was found to have a lower risk of developing diabetes than the hypopharynx and supraglottic (9.4 and 8.9%, respectively). 10% of those with OSCC have DMs 1–76 months following major surgery, according to reports. Because DM has a poor prognosis and reduces patients' quality of life, improving DM treatment is essential. Japan accepted the administration of cetuximab, oral EGFR inhibition, in December 2012 for the treating of heads and neck squamous-cell carcinoma that is both local advanced (LA) and highly prevalent (RM) (HNSCC). In phase III trials, it was discovered that when cetuximab was used with radiation therapy for LA HNSCC and metal chemotherapeutic for R-M HNSCC, there was a significantly higher response rate and an improvement in overall survival (OS)[4]. Cetuximab and paclitaxel are also said to work well together to treat R-M HNSCC when platinum-based chemotherapy does not. However, it is yet unknown how well cetuximab works for DMs. The goal of this retrospective study was to determine the safety and effectiveness of cetuximab treatment in individuals with LA & R-M OSCC, with a focus on those who had DMs. Oral medicine administration raises a number of scientific questions that could be studied for years to come. Moreover, cutting-edge technology must be used to develop novel delivery systems that increase the standard for drug delivery. This article examines some problems with oral medicine distribution that could be fixed by using novel ideas. A technique known as sustained release oral drug administration concentrates medication distribution for locally (or) general activity in a particular section of the GI tract by giving drugs oral continuously for just a predetermined period of time while the digestive tract is being processed. Regardless of the mode of administration (immediate, prolonged, or controlled drug release) and the dosage form design (solid, dispersion, and liquid), all pharmaceuticals intended for systemic administration through the oral dosage forms should be developed inside the innate properties of Gastro intestinal physiology. Research and development on rate-controlled oral drug administration methods have advanced scientifically and technologically in recent years by overcoming physiological constraints such as a short time of gastric residence (GRT) and variable stomach emptying periods (GRT). A floating route of administration (FDDS), also called as hydrodynamic dynamically balanced system (HDS), swelled & extending method, polymeric bio

adhesive systems & modified-shape systems, greater systems, and also other delayed gastric emptying devices are some of the techniques now in use. controlled-release oral tablets should also be made to stay in the stomach for extended periods of time & released for longer periods of time in order to maximise the drug's bioavailability, decrease dosing frequency, and enhance patient compliance[5].

Lollipop: To lubricate and comfort delicate throat tissues, a little piece of medicinal sweets that should melt slowly in the mouth is recommended. a very little, flavoured tablet with sugar or syrup that is typically therapeutic in nature. a tiny, dissolvent treatment for sore throats that was once in the form of a lollipops. Lollipops are large, multi-flavored, sugar-boiled confections that are attached to a plastic stick and can be gently relished by licking them[6]. The plastic stick holds the dessert together. Lollipops are the easy-to-swallow dosage forms that dissolve gently in the mouth and are steadily gaining popularity, especially with young people. Lollipops include a solid solid dosage form of medication that needs to be absorbed inside the mouth or throat. The first lollipops were made in the 20th century, and they are still produced today. Most formulations for lollipops are offered as over-the-counter medicines[7]. Due to its numerous advantages, lollipops are a well-liked dose delivery strategy in the pharmaceutical sector. They do, however, have some shortcomings. The dosage forms have a range of active components and can be utilized for both systemic and local therapy. Lollipops are a particular kind of solid candy that should dissolve gently in the mouth[8]. They often contain one (or) more medication on a foundation that is usually flavoured and sweetened. Lollipops are typically used for instantaneous effects inside the mouth[9]. They can also be used for systemic effects if the medicine is well absorbed through the buccal lining (or is swallowed).

Dental anatomy and physiology of Human tooth

The dosage forms can be used for both systemic and local therapy and have the capacity to contain a wide range of active ingredients. A solid treat that should softly melt on the tongue is a lollipop. They frequently have one or more drugs in a foundation with lots of flavour and sugar. To give oral results right away, lollipop use is common[1]. When the medication is effectively absorbed via the oral lining, they can also be employed for systemic effects (or swallowed). The study of

dental anatomy focuses on tooth structure. The goal of this taxonomy discipline is to describe and categorise tooth and their structural elements so dentists may quickly identify them when treating patients. A human tooth has three anatomical components: a crown, neck, and root. The region above tooth's neck is known as the crown, and the area of the tooth which is covered in gum is known as the root, as you can see in figure 1 below. In addition, whereas incisors and canines usually have a single root, the mandibular (lower jaw), first maxillary premolars, and maxillary (upper jaw) teeth structures all have two or three roots. Moreover, humans develop two teeth sets known as diphyodont, also known as the "deciduous & permanent" sets. Other mammals behave similarly to how we do[10]. The original set, sometimes known as "milk teeth" and "primary tooth," typically consists of 20 primary teeth that appear about six months of birth and 32 permanent (adult) gums that emerge as humans age. Ten of the twenty primary teeth are located in each of the maxilla and mandible, producing the dental formula I2/2, C1/1, PM2/2, and M0/0. The primary group of teeth includes the central & lateral incisors, as well as the first and second molars. Most often, all primary teeth are finally replaced by permanent teeth. Diphyodont are two sets of molars that humans eventually acquire[11]. They are often referred as the "deciduous & permanent" sets of teeth. Humans act in a manner that is similar to that of other mammals[12]. The initial set, also referred to as "milk teeth" and "primary teeth," typically consists of 32 permanent (adult) gums that occur as people age and 20 primary gums that erupt around six months after birth[13]. The 20 primary tooth are distributed across the mandible and maxilla giving rise to the dental formulas I2/2, C1/1, PM2/2, & M0/0. And first and second teeth as well as the lateral and central incisors are all part of the primary group of teeth. Eventually, all primary teeth are frequently replaced by permanent ones.

Types and layers of human teeth

Premolars, molars, incisors, and canines are the four different types of teeth in humans. The following diagram illustrates the typical arrangement of teeth in the mouth, which includes 32 permanent teeth and 20 primary (replaceable) teeth. The primary teeth serve a variety of functions, including cutting and tearing food with incisors and canines and grinding food with premolars and molars. Moreover, teeth have three additional types of layers: major (enamel),

secondary (dentine), & tertiary (calculus) (pulp cavity). Enamel, one of the four main tissues that comprise a tooth—the others being dentin, the pulp chamber, and the cementum—is the tooth's whitest, hardest, and also most mineralized layer, accounting for around 96% of its total mass. Water and organic matter make up the final 4% of a tooth's composition[14]. Enamel typically ranges in colours from light yellow to grayish white, possibly with a faint blue undertone and being semi-transparent. The colour of any restorative dentistry materials and the dentin beneath the enamel greatly affect how a tooth appears. hydroxyapatite, and crystalline calcium phosphate mineral that gives enamel its strength and brittleness, is the primary component that makes up enamel. Amelogenins, enamelin, tuftelins, and ameloblastins are further important proteins involved in the formation of enamel. After enamel, the dentin is a porous layer that is the second-most visible on a tooth. It is less fragile but less prone to degradation than enamel and is made up of 70percentage inorganic,

20percentage organic, and 10percentage water by weight. It supports teeth & decays more quickly the enamel is broken or not managed appropriately[14]. Dentin is produced through a process known as dentinogenesis, which is characterised by the presence of microscopic routes (dental tubules) which also run from of the pulp cavity to the enamel border with teeny side branches. In the dental pulp, odontoblasts secrete dentin[15]. Nerves and blood vessels enter the pulp cavity, also known as the internal part of the teeth, through a hole at the end of the root. The pulp cavity was made up of soft fibrous tissue. Another name for pulp cavity is "the nerve" of a tooth. Around 45% of cementum's composition is inorganic, 33% is organic, and 22% is water. Cementum is a bone-like, specialised substance that covers and attaches to teeth for stability. It is softer than both dentin and enamel. Acellular cementum, which covers around two-thirds of a root & one-third of its root apex, is another type of cement that is present.




Figure 1: Anatomy of the oral cavity

Pathogenic microbiota of human teeth:

This article's section is devoted to the main pathogenic microbiota & dental infections,

the ecology & niche of oral flora, a function of pathogens in maintaining oral health, teeth infections and related problems in the mouth, as

well as the explanation for why the mouth is a favourable environment for microbes. Facts on gum disease from the a biological and clinical standpoint: According to research on oral infections from the domains of medical microbiology & bacteriology, the human mouth is home to 200–300 varieties of bacteria, but only a limited number of these species cause tooth caries or periodontal disease[16]. Certain bacteria that produce acid and adhere to the teeth surface to develop bacterial spores known as oral plaque are the culprits behind

dental decay. The decay that results from this procedure permanently dissolves teeth substance. *Streptococcus mutans* is often responsible for dental decay, and several lactobacilli are connected to the development of the lesion. Pathogenesis research has shown that frequent consumption of fermentable foods maintains the plaque's low pH and results in a net mineral loss from the tooth. Hence, aciduric species like streptococcal bacteria benefit from this low pH.




Fig 2: Pathogenes microbiota of human teeth.

When the condition is close to the dental pulp, caries develops quite unpleasant clinical symptoms. Innovative and chair-side culture methods enable an estimation of the Salivary *Streptococcus mutans* organisms count in accordance with microbiological diagnostics. According to Dzik, et al. and Page, periodontal disease can begin when the roots separate from the tooth as a result of an inflammatory response to plaque[17]. Mixed periodontal infections are frequently caused by anaerobes such *Treponema denticule* and *Porphyromonas gingivitis*. *Actinobacillus actinomycetemcomitans*, according to Zamboni, is the cause of the uncommon ailment known as localised juvenile periodontitis. The pathophysiology of plaque bacteria has revealed that various elements (H₂S, NH₃, amines, toxin, enzyme, antigens, etc.) trigger the protective inflammatory process that also results in periodontal loss, the formation of pockets, molar loosening, & tooth loss. In many industrialised nations, dental, dentifrices, and also the widespread the use fluoride inside the water supply or other items have all helped to reduce a prevalence of caries in young people by 30 to 50%. When detected *Streptococcus mutans* infection are treated with contemporary antimicrobial medications in clinical studies, deterioration is often markedly decreased. to frequently eradicate *Streptococcus mutans* infections that have been identified.

People's oral microbiota consists of the following. The majority of the bacteria that make up the oral microbiome have developed resistance for their benefit and also to affect the immune system of individual dental cavities. Oral microbiology is the study of oral microbes and how they interact with hosts. Because the human mouth provides a groundwater, nutrients, and a temperate temperature, it makes for the perfect setting for the growth of oral microbiota[18]. The tooth and gums are covered in the microbial community that lives in the mouth. Among the bacteria found in the human oral cavity are *Streptomyces*, Initial stage of development, *Bifidobacteria*, *Bifid bacteria*, *Bacteroides*, *Flavobacterium*, *Lactobacillus*, *Leptotrichia*, *Pepto cocci*, *Pepto staphylococcus*, *Propionibacterium*, *Selenodonts*, *Treponema*, & *Villanella*. The bacteria that dwell in the tissues of the mouth, which includes the epithelial and tooth surfaces, include fungi like *Candida*, *Clade*, *Cryptococcus*, and *Penicillium*. The other hand, innate host defence mechanisms constantly track bacterial colonisation and stop bacteria growth of tissues. According to how oral microorganisms function, tooth decay and periodontal disease are the two main dental ailments. The impacts of the oral microbiota on heart health & cognitive function are linked to poor dental health, according to studies[19]. There are also no bacteria in a newborn baby's buccal mucosa, but

Streptococcus oral, Streptococcus mutans, & Streptococcus sanguinis start to colonise the mouth as soon as tooth start to come in. Saliva has a major influence on the oral microbiota, and it primarily inhabits the surfaces of the mouth's interior. More than 800 bacterial isolates species have been identified to have colonies in the oral cavity, suggesting that human mouths are suitable homes for many different bacterial species because of the availability of nutrients and watery saliva that flow through on a daily basis. 80 million distinct types of bacteria from various species also exchanged saliva during a 10-second kiss. But, the effect is only fleeting because everyone soon regains their own composure. According to scientific study on oral ecology as well as molecular biology methods, these communities of bacteria exist in the mouth ecology, and includes the tongue, tooth, gum, salivary glands, or other structures. a wide range of microorganisms. The host's immune system controls oral bacterial colonisation and prevents local tissue infection. Due to a dynamic balance between the organisms in the plaque as well as the host's immune system, dental plaque can continue to accumulate in the mouth long after other bacteria have been eliminated. Saliva quickly eliminates the bacterial biofilm formed by fermentation of sugar in a healthy mouth, in addition to dental plaque[20]. One example of an oral condition caused by unchecked oral bacteria in an environment of equilibrium imbalance is periodontal infection and tooth decay. A resistant bacteria infection has also been linked in studies to poor tooth care.

The role of pathogenic microbiota in oral health:

Several aspects of the human mouth can prevent pathogenic mouth microbiota from producing disorders of the mouth. Dental plaque is mostly adhered to teeth by two species of bacteria called Streptococcus mutans & Streptococcus sanguis, whose extracellular secretions and saliva make up the majority of the plaque[21]. If not eliminated by brushing, plaque, which is a deposit of germs on the tooth that causes dental disease, turns into the a hardened form of gum disease. Moreover, several fungi, such as Alternaria, Aspergillus, Candida, Clostridium, Cryptococcus, Fusarium, Glomus, & Penicillium, as well as oral microbiota bacterial species that are associated with being present in vaginosis bacteria in women are regularly discovered in human mouths. Human vaginosis has also been linked to these species[22]. Furthermore, high blood levels of antibody to oral infections are linked to hypertension in people, and

poor oral health brought about by oral microbiota entering the human body might affect cardiac function.[23]

human infections of the mouth and teeth: Anne and Naomi assert that the mouth is a major reservoir for the microorganisms that result in oral and dental infections, including post-extractional infections, periodontal disorders, gingivitis, pericoronitis, endodontitis, and periimplantitis[24]. Oral infections have been associated with the following bacterial species: Actinobacillus actinomycetemcomitans, Bacteroides Forsythus, Campylobacter rectus, Eike Nella corrodens, Eubacterium organisms, Fusobacterium nucleatum, Pepto staphylococcus micros, Porphyromonas gingivitis, as well as Prevotella intermedia[25]. In medically weak people, particularly those with AIDS, superinfection with enteric & Candida species frequently makes oral infections worse. Often, similar species are connected to these illnesses[26]. To isolate those species that cause mouth infections, the appropriate samples must be collected, and only anaerobic techniques should be used. Rapid selective cultures, immunofluorescence, & DNA probe techniques are some of the methods for determining these buccal species that have been developed. Antibiotic therapy is one of several methods used to treat infection in the teeth and mouth. An reliable microbiological identification, which may involve an antibiotic susceptibility test, is required in cases that do not improve after therapy[27]. Dental infections & dental health hygiene in people have a variety of impacts on the body. The main impacts of oral pathogenic germs and the consequences of poor dental hygiene are summarised in the explanation that follows. Oral pathogenic microorganisms have the following effects: The accompanying pictures 2 depict a variety of dental problems that can result from pathogenic microbiota & poor oral hygiene, such as pathologic attrition on the occlusal surface, erosion of the tooth, abrasion, hypocalcified amelogenesis interact, and attrition. In accordance with the Mendelian hypothesis of human inheritance, variations in tooth size, shape, and quantity can result from a range of acquired & inherited developmental abnormalities. All dentists should be conversant with this corpus of knowledge, even though each piece of it is uncommon when considered separately. Oral pathology is a feature of several inherited illnesses, including ectodermal dysplasia and dentinogenetic imperfecta[28].

Charles (2004) These unusual features of human teeth are best described by the following definition. The physiologically normal wear of teeth results in attrition, which is the loss of tooth surface. Pathologic acceleration of wear, however, extends beyond physiologically normal. When you consume too many acidic food or drink, you can get erosion, which is the chemical destruction of tooth structure. Abrasion is often used when there is a loss on a non-occluding surface. The occlusal & incisal surfaces are typically the only places

where it can occur mechanically. With the uncommon disorder known as amelogenesis imperfecta, the formation of enamel has inherited defects. It only affects roughly 1 in 14,000 people and has at least 14 recognised symptoms. It is inherited by autosomal dominant, recessive, & X-linked pathways. It is not the quantity the enamel that is the issue, but rather the quality of it. Hypocalcified enamel was weakly mineralized, fragile, chippable, and easily worn[29].



Fig 3 : Human teeth infections.




Fig 4: human mouth illness.

Diastema, regional odontodysplasia, dental dysplasia, imperfect amelogenesis, & dentinogenesis imperfecta are additional anomalies in the architecture of human teeth. When the disease dentin dysplasia also impacts the roots & pulp cavity of human teeth, the conditions amelogenesis imperfecta & aentinogenesis imperfecta occur[30]. These conditions are characterised by improper formation of enamel and dentin, respectively. A gap between teeth caused by an imbalance between size of a jaw and or the enamel, dentin, & pulp cavity of the tooth is known as a diastema. An issue with the enamel, dentin, and pulp cavity of the teeth known as regional odontodysplasia influences how human teeth develop[31]. Dental caries, or tooth decay caused by infectious infections that can lead to tooth pain, loss of teeth, and damage to a structures of the teeth, is depicted in Figure 3 as occurring in a human[32]. Dental caries continues

to rank one of the most common chronic diseases worldwide, and changes on nutrition have been related to an increase in the prevalence of the condition. In the US, where 60-80% of children, or 20percent of the population, have dental caries, the prevalence is at least five times higher than that of asthma. 60 to 80 percent of people in Europe have dental caries[33]. Tooth decay, the most serious damage to teeth, is caused by specific types of bacteria that create acids when carbohydrates like glucose, fructose, & sucrose were present in the mouth. The American Dental Association states that because teeth have special mineral compositions which make it sensitive to low pH, it mouth's ensuing acidic levels have an effect on teeth (2011). Furthermore, acid-producing foods which are left on the tongue, mouth, and teeth can erode enamel & cause cavities, which eventually expose the uncomfortable pulp[34].



Fig 5: Chronic dental infections.

Plaque is a biofilm composed of several bacteria that amass on teeth in large quantities, according to studies from of the American Dental Academy (2011), Ross (2002), & Elmhurst College. If plaque is not removed on a regular basis, periodontal problems like gingivitis may arise. Tartar can develop from plaque if it is allowed to mineralize along gums over time. Where in the mouth the biofilm is found determines its microbial composition, which is almost entirely made up of microorganisms (mostly streptococcus and anaerobes)[35]. Most significantly, a bacteria called Streptococcus mutans is linked to dental caries. Some mouth bacteria feed in leftover food, especially sugars and carbs. Lack of oxygen causes them to produce lactic acid, which breaks down the calcium and phosphorus in the enamel. The rotting of teeth is brought on by a process called "demineralization." When saliva gradually counteracts the acids, a pH of the teeth increases above critical pH, that is considered to be 5.5[36]. As a result, the dissolved minerals return to the enamel, a process known as "remineralization." dental care treatments and methods: Acid-producing foods can erode tooth enamel & eventually expose the pulp-filled nerve, leading to tooth decay. Since this hurts, the cavity must be drilled out, cleaned, and filled by gold, silver amalgam fillings (a mercury alloy), gum composites, ceramic, or inlays. People practise good oral hygiene to avoid dental caries, gingival, periodontal disease, bad breath, or other dental problems[37]. Tartar can be removed from your teeth by dental hygienists & dentists by thoroughly brushing and flossing them on a regular basis. According to the American Dental Association, the purpose of brushing teeth is to remove plaque, which is mostly made up of bacteria. Regular brushing daily is recommended by medical professionals to maintain healthy teeth and gums[38]. The controversy surrounding electric toothbrushes in 2003 was explained by (BBC) News as being caused by a common substance used to protect individuals. For oral hygiene to be

effective, it must be practised correctly; otherwise, major problems with human oral health may occur. Humans require proper dental cleanliness to safeguard pathogenic oral microbiota, prevent tooth loss, stop tooth decay, and avoid additional problems including cardiovascular, diabetic, and osteoporosis illnesses, which are all linked to poor dental health[39]. As a result, it's imperative to brush the teeth every day, maintain a regular cleaning, & maintain a balanced diet to avoid any negative impacts brought on by bad oral hygiene. Maintaining proper dental functionality also necessitates fluoride therapy & dental sealants in addition to maintaining appropriate oral hygiene. The hydroxyapatite crystals found in the outer layer of a tooth's tooth are what fluoride treatment attaches to in order to stop dental decay, according to Cate (1998). According to Ross (2002), fluoride is yet another preventive therapy which is frequently used to strengthen enamel's resistance to demineralization, which makes it more resistant to decay. Dental sealants are another preventive treatment that dentists frequently use to deliver a fence to bacteria & decay on the surface of the teeth[40].

Cetuximab drug of choice for gums cancer

The sixth most common type of cancer in the world is oral squamous cell carcinoma (OSCC), which accounts for 2.3 percent of all cancers in people. The prognosis for (OSCC) is continuously dismal. It is still fatal in more than 50% of cases that are diagnosed each year. A most of (OSCC) patients are currently managed and treated surgically, and concomitant postoperative chemoradiotherapy is considered the gold standard of care for high-risk (OSCC)[41]. Although overall survival (OS) has not significantly improved as a result of this treatment plan, locoregional control and disease-free survival have. Although the risk factors behind the lack of advancement in (OS) are yet unknown, single potential risk has been proposed: distant metastases (DM)[42]. It was observed to occur inside the neck and head. that the

areas with a were the supraglottic and hypopharynx. Diabetes (9.4 and 8.9%, respective) at a greater risk, whereas the risk for the oral cavity was lower (3.2%). According to reports Approximately 10% of people experience DMs 1–76 months following major surgery. sufferers of (OSCC). (DMs) lower the sufferers' quality of life. of life and have a dismal outlook, enhanced care for (DMs) is a crucial factor to consider [43]. The epidermal growth factors receptor cetuximab (EGFR) inhibitor, was licensed to treat locally affluent recurrent metastatic head and neck cancer that is advanced (LA) and HNSCC, or head and neck squamous cell cancer, in December 2012 to Japan. Cetuximab was shown in phase III trials to have a greater response rate and a significant improvement in OS when administered in combination with radiation in (LA HNSCC) and platinum-based chemotherapy in (R-M HNSCC). Moreover, when platinum-based chemotherapy fails to treat (R-M HNSCC), cetuximab combined with paclitaxel is said to be effective. Cetuximab's effectiveness for DMs is still unknown. This retrospective study's objective was to evaluate the safety and efficacy for cetuximab treatment in patients having (LA and R-M OSCC), with a focus on those who had (DMs) [44].

Patient and method

Study design: We looked back at the data of patients who received cetuximab between December 2012 and July 2015 and had diagnosed unresectable (LA) and (R-M OSCC) (cetuximab group). The competent ethics board of our Nagasaki University Hospital gave its support to this investigation. The time to disease progression was the trial's endpoint, and we looked at the tumour response rate, progression-free survival (PFS), overall survival (OS), and safety. As long as treatment was being administered, the best overall response was judged in accordance with the Response Assessment Criteria in Solid Tumors. Tumor response was examined every 4–8 weeks with repeated clinical and improved computed tomography (CT) assessments [45]. (PFS) was determined as the period of time from the initial cetuximab delivery to the earliest of (PD) or recurrence. (OS) was determined to be the period of time between the administration date of cetuximab and the death date. The Kaplan-Meier method was used to generate the survival distributions, and the log-rank test was used to compare them. Clopper and Pearson's two-sided confidence intervals (CIs) were computed. The

National Cancer Institute's Popular Terminology Criteria for Adverse Events, version 4.0, were used to evaluate the toxicity of substances [46].

Treatment: According to the Bonner study, cetuximab plus radiation, cetuximab plus cisplatin and 5 fluorouracil, paclitaxel and cetuximab were the regimens employed in our department. Blood tests were used to determine the serum levels of Krebs von den Lungen 6, surfactant protein A, and surfactant protein D. Plain radiography and a chest (CT) were also conducted to check for interstitial pneumonia. The serum levels of antibodies to ticks, mammalian meat, and flatfish were also examined for allergy and particular (IgG) antibody titres [47]. The initial injection of cetuximab was given at a dose of 400 mg/m², and subsequent injections were given at a dose of 250 mg/m². On day 1, 100 mg/m² of cisplatin was delivered, and over the next four days, 1,000 mg/m² of 5 fluorouracil. Every week, paclitaxel was given at a dosage of 60–80 mg/m². The dosage was chosen based on the person's overall health. Patients who at least had stable disease (SD) got cetuximab therapy up until progressive disease (PD) or unacceptable toxic effects [48].

II. RESULT

Patient characteristics: 21 patients were included in the survey; 47.6% of the victims are males & 52.4 percent were female, and 20 patients had a performance status of 0 or 1. The clinicopathological characteristics of the patients were collected over a period of 2 years and 6 months. The patients' average age was 73 years (range, 51–88 years). Mandibular gingiva (52.4%), tongue (23.8%), or maxillary gingiva (9.52%) were the most typical sites for primary tumours. Adenomas cell carcinoma (n=1, 4.76%), heteroleptic sarcomas (n=1, 4.76%), myoepithelial myeloma (n=1, 4.76%), amorphous carcinoma (n=1, 4.76%), and unclear (n=1, 4.76%) made up the remaining 5 tumours on the basis of pathological examination, which revealed that 16 of the 21 tumours were SCCs (76.2%). Prior to the delivery of medication, immunostaining was used to confirm an overexpression of EGFR in each of the 5 non-SCC instances. Three patients (14.3%) had LA cancer, while 18 (85.7%) had R-M carcinoma. 18 patients had received prior treatment: 2 had received surgery and adjuvant radiation (9.5%), 8 had received surgery and adjuvant chemoradiotherapy (38.1%), and 8 had received surgery alone (38.1%). Regarding initial treatment regimens, 9 of the 21 tumours had

received cetuximab plus radiation (42.8%), 9 had received cetuximab plus paclitaxel (42.8%), 2 had received cisplatin and cetuximab plus 5fluorouracil

(9.5%), and 1 had received cetuximab alone (4.8%). Nine treatment sessions with cetuximab were the average number (range, 0-70)[49].




Fig 6: Cetuximab treatment null hypothesis.

Efficacy: Table II provides the specifics of both all instances and DM cases. With a full response rate of 33.3% or a partial response rate of 23.8% (95% CI: 7.7–47.6%), an overall response rate were 57.1% (95% CI: 33.7–78.2%). (95% CI: 42.7–85.4%), the illness controlling rate (PR plus SD) was 66.7%. Two patients had malignancies that were resistant to cetuximab. 5 patients originally had disease control, however they later experienced (PD). Two of these patients developed brain metastases while receiving cetuximab, despite the fact that one of them had locoregional and lung metastasis under control. PFS and (OS) at 1 year were 43,1 and 52,7%, respectively. An median (PFS) and OS were 5.5 months and 8.0 months, respectively, with 95% confidence intervals of 3.5 to 10.5 months and 5 to 13 months (Fig. 1)[50].

Medicated lollipop

A little, medicated candy that should melt gradually in the tongue to lubricate and soothe sensitive throat tissues a little, flavoured tablet that is frequently medicinal and consists of sugar or syrup. a little, oral medication that is dissolved for sore throats and was once shaped like a lollipop. Large sugar-boiled confections in a variety of flavours affixed to the a plastic stick are known as lollipops, which can be savoured slowly by licking them. The dessert is held together by the plastic stick. Lollipops are the dose forms that disintegrate gradually in the mouth or that are simple to swallow, and they are becoming more

and more common, especially with young patients[6].The medication found in lollipops is a solid unit route of administration that should be disintegrated in the mouth or pharynx. Lollipops were first created in the 20th century and are still manufactured for sale. The majority of lollipops formulations are sold when over drugs. Lollipops offer a tasty method of administering dose forms, and they are popular in the pharmaceutical companies due to their many benefits. But they also have significant drawbacks. The dosage forms can be used for both regional and systemic treatment, and they can contain a variety of active pharmaceutical ingredients. Lollipops are a type of solid confection that is meant to break down gradually in the mouth. With a typically flavoured, sweetened basis, they typically include one (or) more medication. The majority of the time, lollipops are employed for direct consequences in the mouth. If the medication is well absorbed via the buccal lining (or) is eaten, they can also be employed for systemic effects[51].

Advantages Of Medicated Lollipops


1. Possessing formulae that are flexible and adaptable to individual patients
2. Continuing to expose the oral cavity to the medications for a long time.
3. Also, a pharmacist can make lollipops since they have a tasty texture and prolong the time that a dose of medication stays in the mouth to have a therapeutic impact. impromptu with little preparation and time.

4. Lollipops can be administered to people who have trouble swallowing.
5. It prolongs the amount of time a substance remains in the mouth before having a particular effect.
6. Simple to create with little effort and time required
7. Don't need to drink any water to administer. As with injectable, the method is non-invasive.

Disadvantages Of Medicated Lollipops

1. Due to the high temperatures needed for manufacturing, medicines that are heat labile cannot be utilized in this formulation.
2. Medicines with a little bitter flavour are appropriate.
3. Medicines that are heat stable are appropriate.

TYPES OF LOLLIPOPS



HARD LOLLIPOPS

It's possible to classify hard lollipops as solid sugar syrups. These pills are manufactured by combining sugar and other materials, boiling it, and then putting the resulting substance into a mould. Hard candy is akin to hard lollipops. In actuality, many hard lollipops' recipes are alterations of hard candies'. The dose form requires little moisture. Hence, during the compounding process, water is removed by heating the sugar mixture. Lollipops are amorphous (noncrystalline) or glassy combinations of sugar and other carbohydrates. These lollipops typically have a moisture level of 0.5%-1.5% and can be regarded as solid sugar syrups. Hard lollipops should slowly dissolve or erode over the course of 30 minutes rather than disintegrating abruptly.

SOFT LOLLIPOPS

Because of how simple it is to make soft lollipops on the spot and how well they work with so many different medications, they have gained popularity. The basis is typically made up of a combination of different PEGs, acacia (or) related materials, glycerol gelatin, or an acacia: sucrose base. Depending on the intended impact of the drug contained, these lollipops may be coloured and flavoured. They can either be eaten or gradually disintegrated in the mouth[9].

METHOD OF PREPARATION

Lollipops are prepared by heating and congealing technique.

HEATING AND CONGEALING TECHNIQUE

1. To make a syrupy base, dissolve the necessary quantity of sugar in a pot of water and heat it to 1100°C for around 90 seconds.
2. Increasing the heating to 1600C and adding the foundation syrup.

3. A cooling process to produce the plastic bulk
4. The addition of a substance for blending with a polymer, colour, or flavour.

5. After drying, the materials are sized roped in a rotating roller.

6. Use polyethylene covers to package things

The weight of the lozenge utilising the specific base of interest must be determined by calibrating the moulds used to produce troches and lozenges. The next steps can be taken to accomplish this.

1. Get the lozenge mould ready and ensure that the cavities are dry and clean.

2. Gather and melt enough lozenge foundation to fill 6 to 12 moulds.

3. Once the moulds have been filled, let them cool and, if required, trim.

4. Eliminate the lozenges, then weigh.

5. To determine the average weight of each lozenge for this specific base type, divide the total weight by the quantity of made blank lozenges.

Formulation of cetuximab as buccal dissolving lollipop Composition

The medication is an intravenous infusion-ready sterile liquid formulation containing 100 mg

of cetuximab per vial. Table A provides a summary of the formulation's composition as well as the separate constituents' roles and quality requirements.

Table A. Composition of cetuximab

Component	Amount per vial	Amount (mg/ml)	Function	Quality standards
Cetuximab, chimeric antibody	100 mg	2 mg/ml	Active ingredient	In-house specification
Sodium chloride	424 mg	8.48 mg/ml	Isotonicity agent	Ph. Eur.
Sodium dihydrogen phosphate dihydrate	20 mg	0.40 mg/ml	Buffer	Ph. Eur.
Disodium phosphate dihydrate	66 mg	1.32 mg/ml	Buffer	Ph. Eur.
Water for injection	ad 50 ml*	ad 1 ml	Diluent	Ph. Eur.

Table 1: Cetuximab lollipop formulations.

Cetuximab solution in the range of 50.5 to 52.0 ml is the action level for the filling technique. The patient is not at risk as a result of this overflow, which ensures the required extractable amount of 50 ml, as the dosage to be given is calculated and monitored for each individual patient. In 50 ml type 1 glass vials with a Teflon-coated, bromobutyl rubber stopper, the medicinal product is provided at a concentration of 2 mg/ml. The principal packing components are both of Ph. Eur. quality[8].

Active substance

Manufacturing and management of raw materials

The monoclonal antibody cetuximab is a mixture of human and mouse. On each of the two heavy chains of cetuximab, there are two N-linked carbohydrate sites. Cetuximab has a molecular weight that, with carbs, is roughly 152 kDa. A stable transfected murine myeloma cell line produces the recombinant protein. When creating a drug compound, a holding phase called concentrated bulk is added. Alteration of concentrated volume in formulation buffer is all that is required to create the active ingredient in a drug. Similar techniques are used at two different locations for the manufacture: ImClone (IC or CS-US) and Boehringer Ingelheim (BI or CS-EU) both

generate concentrated bulk for shipment and drug substance, respectively. The two commercial processes, CS-US and CS-EU, which stand in for IC and BI, respectively, are described in detail. One Working Cell Bank (WCB) vial produces one sample or concentrated bulk material at each production site. After divided or combined, this mass can make up the drug material, which has a 2 mg/ml concentration.

Cell culture and harvesting

Cell culture is used to create cetuximab in batch mode in stirred tank bioreactors that are 10,000 L or 12,000 L in size (IC and BI, respectively). WCB is defrosted, and all subsequent cell culture stages are carried out in serum-free medium. Purification. At 0.2 m, diafiltration is used to concentrate and sort the cell-free media. According to purification, any group of concentrated bulk produced by fermentation is equivalent to one batch of that product. The last step in the purification process is diafiltration into the formulation buffer. Filtered for sterility, this solution has a shelf life of one year at 2 to 8 degrees Celsius. Dilution of the concentrating volume to 2 mg/ml in formulating buffer is used for the final production of the medicinal material.

Gene construct

The mouse monoclonal antibody M225's variable region cDNAs and the cDNAs for the human kappa and gamma 1 known as the coefficient are used to encode the chimeric antibody. The cDNAs are added to the vector of expression with distinct expression cassettes for the heavy and light chains, respectively.

Cell banking system

It has been sufficiently detailed how to prepare established cell banks, and the stability and safety tests that have been carried out are in line with EU recommendations. The cell banks that are of concern for manufacturing have undergone a complete genetic characterisation, which includes independent examinations of the production units for the heavy and light chains and the light chain. The level of control used to produce this transgenic product is deemed adequate in general. The cell cultures used have adequate documentation.

Control of steps

Three types of tests are included in in-process testing: in-process specifications, in-process control parameters, and in-process monitoring. From the inoculum through the production fermentor, the regulation of cell culture is mostly dependent on viability and purification from microorganisms. The used cell bank paperwork is appropriate [52].

Evaluation of cetuximab buccal dissolving lollipop

The following factors were assessed for the lozenges and tablets that had been developed.

1. THICKNESS

Vernier callipers were used to measure the formulated lollipops' thickness and diameter.

2. WEIGHT VARIATION

The homogeneity of the weight of the developed lollipops was evaluated. There were 20 tablets total, each one separately. The average weight was determined from the total weight. The average weight of lollipops was then used to compare each lollipops' weight to determine whether it was within acceptable bounds or not.

$$\% \text{ Weight Variation} = \frac{\text{Average weight} - \text{Individual weight}}{\text{Average weight}} \times 100$$

Average weight

3. HARDNESS

Using a Pfizer tablet hardness tester, the lollipops crushing strength—the amount of force needed to break the candies by compression in the opposite direction—was measured three times.

4. FRIABILITY

The friability of the lollipops was evaluated using the Roche friability test equipment. The device was filled with 5 pre-weighed lollipops and rotated 100 times. The lollipops were then weighed again. The formula was used to calculate the percentage of friability.

$$\% \text{ Friability} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100$$

weight

DRUG CONTENT

Lollipops were measured and pulverised. The amount of powder goal of 100 mg was dissolved in buffer and diluted to 100 ml with buffer, after which the solution was filtered and appropriately diluted. Spectrometric analysis was used to determine the drug content.

IN VITRO DISSOLUTION STUDIES

In 900 ml of 37.5°C at 100 rpm, the dissolution rate was examined using the USP II paddle dissolving device. At predetermined intervals, an aliquot of the dissolution medium was removed, and the same volume of freshly prepared, pre-warmed (37.5°C) dissolution media was substituted. The samples were filtered, and following the appropriate dilution, each sample's drug content was examined using a Shimadzu UV-spectrophotometer [53].

III. CONCLUSION

The significance of cetuximab in the treatment of oral cancer is expanding because it has been used successfully in people with the disease. The acceptance of cetuximab with irinotecan as part of the conventional treatments in that context has been accepted by community recommendations like the NCCN. Recent clinical studies have shown that cetuximab shows potential activity in second-line (Engstrom 2007). In individuals with refractory disease, encouraging action has also been seen in first-line treatment when paired with FOLFIRI, FOLFOX, and regimens incorporating bevacizumab. Recently in certain types of oral cancer such as gum cancer newly discovered lollipop were used probably with loading different cytotoxic drugs as cetuximab which it used

individually or combination with other chemotherapy as a novel drug delivery system utilized for gum cancer management.

REFERENCES

- [1]. M. T. Hamed and H. A. Mously, "Investigating economic and clinical implications of tooth implant supported prosthesis among patients and practitioners," *Int J Pharm Res Allied Sci*, vol. 8, no. 4, pp. 116–121, 2019.
- [2]. C. Dawes et al., "The functions of human saliva: A review sponsored by the World Workshop on Oral Medicine VI," *Arch. Oral Biol.*, vol. 60, no. 6, pp. 863–874, 2015.
- [3]. H. M. H. N. Bandara, C. P. Panduwawala, and L. P. Samaranyake, "Biodiversity of the human oral mycobiome in health and disease," *Oral Dis.*, vol. 25, no. 2, pp. 363–371, 2019.
- [4]. W. Lewinsky and D. Stewart, "The innervation of the human gum," *J. Anat.*, vol. 72, no. Pt 4, p. 531, 1938.
- [5]. V. K. Devi, A. N. Asha, R. S. Pai, M. C. H. Reddy, and M. Raghavendra, "Orodispersible fluconazole tablets-preparation and evaluation," *INDIAN DRUGS-BOMBAY-*, vol. 43, no. 7, p. 548, 2006.
- [6]. F. Firriolo John, "Oral Candidiasis, History, Classification and Clinical Presentation, Oral Surg. Med. Oral Pathol." Louisville, 1994.
- [7]. H. Mohan, "Text book of Pathology–The oral cavity and salivary glands." Jaypee Brothers, Medical Publishers (P) Ltd., New Delhi, 2000.
- [8]. A. H. Shojaei, "Buccal mucosa as a route for systemic drug delivery: a review," *J Pharm Pharm Sci*, vol. 1, no. 1, pp. 15–30, 1998.
- [9]. P. Jagadeesh, P. Jyothi, G. N. Vani, and S. Dasthagiri, "Review of Medicated Lollipops," *World J. Pharm. Res. India*, vol. 6, no. 3, pp. 399–405, 2017.
- [10]. R. Moazzez, D. Bartlett, and A. Anggiansah, "The effect of chewing sugar-free gum on gastro-esophageal reflux," *J. Dent. Res.*, vol. 84, no. 11, pp. 1062–1065, 2005.
- [11]. S. Furness, H. V Worthington, G. Bryan, S. Birchenough, and R. McMillan, "Interventions for the management of dry mouth: topical therapies," *Cochrane Database Syst. Rev.*, no. 12, 2011.
- [12]. A. Ranganath and I. Nasim, "An evidence-based decision analysis approach on tooth discoloration," *J. Adv. Pharm. Educ. Res.* Jul-Sep, vol. 7, no. 3, 2017.
- [13]. B. S. Rubel, "Impression materials: a comparative review of impression materials most commonly used in restorative dentistry," *Dent. Clin. North Am.*, vol. 51, no. 3, pp. 629–642, 2007.
- [14]. J. v Schönfeld, M. Hector, D. F. Evans, and D. L. Wingate, "Oesophageal acid and salivary secretion: is chewing gum a treatment option for gastro-oesophageal reflux?," *Digestion*, vol. 58, no. 2, pp. 111–114, 1997.
- [15]. W. A. Ayer, *Psychology and dentistry: mental health aspects of patient care.* Psychology Press, 2005.
- [16]. D. Berger, A. Rakhimova, A. Pollack, and Z. Loewy, "Oral biofilms: development, control, and analysis," *High-throughput*, vol. 7, no. 3, p. 24, 2018.
- [17]. B. T. Rosier, P. D. Marsh, and A. Mira, "Resilience of the oral microbiota in health: mechanisms that prevent dysbiosis," *J. Dent. Res.*, vol. 97, no. 4, pp. 371–380, 2018.
- [18]. P. P. Hujoel, M. Drangsholt, C. Spiekerman, and N. S. Weiss, "An exploration of the periodontitis–cancer association," *Ann. Epidemiol.*, vol. 13, no. 5, pp. 312–316, 2003.
- [19]. L. Zhang, Y. Liu, H. J. Zheng, and C. P. Zhang, "The oral microbiota may have influence on oral cancer," *Front. Cell. Infect. Microbiol.*, vol. 9, p. 476, 2020.
- [20]. D. Hashim et al., "The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium," *Ann. Oncol.*, vol. 27, no. 8, pp. 1619–1625, 2016.
- [21]. J. Fang, L. Long, and H. Maeda, "Enhancement of tumor-targeted delivery of bacteria with nitroglycerin involving augmentation of the EPR effect," *Bact. Ther. Cancer Methods Protoc.*, pp. 9–23, 2016.
- [22]. R. A. Malmgren and C. C. Flanigan, "Localization of the vegetative form of *Clostridium tetani* in mouse tumors

- following intravenous spore administration,” *Cancer Res.*, vol. 15, no. 7, pp. 473–478, 1955.
- [23]. N. Suzuki, M. Yoneda, and T. Hirofuji, “Mixed red-complex bacterial infection in periodontitis,” *Int. J. Dent.*, vol. 2013, 2013.
- [24]. D. R. Farquhar, K. Divaris, A. L. Mazul, M. C. Weissler, J. P. Zevallos, and A. F. Olshan, “Poor oral health affects survival in head and neck cancer,” *Oral Oncol.*, vol. 73, pp. 111–117, 2017.
- [25]. Y. Asai, T. Jinno, and T. Ogawa, “Oral treponemes and their outer membrane extracts activate human gingival epithelial cells through toll-like receptor 2,” *Infect. Immun.*, vol. 71, no. 2, pp. 717–725, 2003.
- [26]. A. Promsudthi, S. Poomsawat, and W. Limsricharoen, “The role of T oll-like receptor 2 and 4 in gingival tissues of chronic periodontitis subjects with type 2 diabetes,” *J. Periodontal Res.*, vol. 49, no. 3, pp. 346–354, 2014.
- [27]. D. F. Lappin, S. Sherrabeh, and C. Erridge, “Stimulants of Toll-like receptors 2 and 4 are elevated in saliva of periodontitis patients compared with healthy subjects,” *J. Clin. Periodontol.*, vol. 38, no. 4, pp. 318–325, 2011.
- [28]. P. Kamarajan et al., “Periodontal pathogens promote cancer aggressivity via TLR/MyD88 triggered activation of Integrin/FAK signaling that is therapeutically reversible by a probiotic bacteriocin,” *PLoS Pathog.*, vol. 16, no. 10, p. e1008881, 2020.
- [29]. B. Huang et al., “*Listeria monocytogenes* promotes tumor growth via tumor cell toll-like receptor 2 signaling,” *Cancer Res.*, vol. 67, no. 9, pp. 4346–4352, 2007.
- [30]. M. Karin, Y. Yamamoto, and Q. M. Wang, “The IKK NF- κ B system: a treasure trove for drug development,” *Nat. Rev. Drug Discov.*, vol. 3, no. 1, pp. 17–26, 2004.
- [31]. S. G. Dashper, C. A. Seers, K. H. Tan, and E. C. Reynolds, “Virulence factors of the oral spirochete *Treponema denticola*,” *J. Dent. Res.*, vol. 90, no. 6, pp. 691–703, 2011.
- [32]. A. K. Kylmä et al., “*Treponema denticola* chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma,” *Br. J. Cancer*, vol. 119, no. 1, pp. 89–95, 2018.
- [33]. J. M. Doolittle and J. Webster-Cyriaque, “Polymicrobial infection and bacterium-mediated epigenetic modification of DNA tumor viruses contribute to pathogenesis,” *MBio*, vol. 5, no. 3, pp. e01015-14, 2014.
- [34]. R. Pearson et al., “Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency,” *J. Virol.*, vol. 82, no. 24, pp. 12291–12303, 2008.
- [35]. J. E. Kirkpatrick, K. L. Kirkwood, and P. M. Woster, “Inhibition of the histone demethylase KDM4B leads to activation of KDM1A, attenuates bacterial-induced pro-inflammatory cytokine release, and reduces osteoclastogenesis,” *Epigenetics*, vol. 13, no. 5, pp. 557–572, 2018.
- [36]. X. Fan et al., “Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults,” *Microbiome*, vol. 6, no. 1, pp. 1–15, 2018.
- [37]. P. S. Kumar, C. R. Matthews, V. Joshi, M. de Jager, and M. Aspiras, “Tobacco smoking affects bacterial acquisition and colonization in oral biofilms,” *Infect. Immun.*, vol. 79, no. 11, pp. 4730–4738, 2011.
- [38]. J. Wu et al., “Cigarette smoking and the oral microbiome in a large study of American adults,” *ISME J.*, vol. 10, no. 10, pp. 2435–2446, 2016.
- [39]. R. B. Hayes et al., “Association of oral microbiome with risk for incident head and neck squamous cell cancer,” *JAMA Oncol.*, vol. 4, no. 3, pp. 358–365, 2018.
- [40]. D. Lin et al., “Microbiome factors in HPV-driven carcinogenesis and cancers,” *PLoS Pathog.*, vol. 16, no. 6, p. e1008524, 2020.
- [41]. J. Bernier et al., “Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (# 22931) and RTOG (# 9501),” *Head Neck J. Sci. Spec. Head Neck*, vol. 27, no. 10, pp. 843–850, 2005.
- [42]. J. S. Cooper et al., “Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk

- squamous cell carcinoma of the head and neck,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 84, no. 5, pp. 1198–1205, 2012.
- [43]. J.-Y. Lim, Y. C. Lim, S.-H. Kim, J. W. Kim, H. M. Jeong, and E. C. Choi, “Predictive factors of isolated distant metastasis after primary definitive surgery without systemic treatment for head and neck squamous cell carcinoma,” *Oral Oncol.*, vol. 46, no. 7, pp. 504–508, 2010.
- [44]. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” *CA. Cancer J. Clin.*, vol. 61, no. 2, pp. 69–90, 2011.
- [45]. M. Yamasaki et al., “Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus,” *Oncology*, vol. 80, no. 5–6, pp. 307–313, 2011.
- [46]. E. A. Eisenhauer et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” *Eur. J. Cancer*, vol. 45, no. 2, pp. 228–247, 2009.
- [47]. I. M. G. Agra et al., “Biological markers and prognosis in recurrent oral cancer after salvage surgery,” *Arch. Otolaryngol. Neck Surg.*, vol. 134, no. 7, pp. 743–749, 2008.
- [48]. K. K. Ang et al., “Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma,” *Cancer Res.*, vol. 62, no. 24, pp. 7350–7356, 2002.
- [49]. S.-M. Huang, J. M. Bock, and P. M. Harari, “Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck,” *Cancer Res.*, vol. 59, no. 8, pp. 1935–1940, 1999.
- [50]. N. Zhang et al., “Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro,” *Radiother. Oncol.*, vol. 92, no. 3, pp. 388–392, 2009.
- [51]. N. K. Jain, *Controlled and novel drug delivery*. CBS publishers & distributors, 1997.
- [52]. H. Goel, P. Rai, V. Rana, and A. K. Tiwary, “Orally disintegrating systems: innovations in formulation and technology,” *Recent Pat. Drug Deliv. Formul.*, vol. 2, no. 3, pp. 258–274, 2008.
- [53]. A. Herbert, G. B. Lieberman, and L. Lachman, “Pharmaceutical dosage forms. tablet series. Medicated Lozenges.” Marcel Dekker Inc., New York and Basel, 1991.

Abbreviation list

- HPV Human Papillomavirus
OSCC Oral Squamous Cell Carcinoma
DM Distant Metastasis
EGFR Epidermal Growth Factor Receptor
LA Locally Advanced
RM Recurrent Metastatic
HNSCC Head and Neck Squamous Cell Carcinoma
OS Overall Survival
GRT Gastric Residence Times
FDDS Floating Drug Delivery Systems
HBS Hydrodynamically Balanced Systems
H₂S Hydrogen Sulfide
NH₃ Ammonia
PFS Progression Free Survival
CT Computed Tomography
PD Progressive Disease
CI Confidence Intervals
SD Stable Disease
PEG Percutaneous Endoscopic Gastrostomy
IC ImClone
BI Boehringer Ingelheim
CSCowden Syndrome
US Ultra sonogram
EU Eupnoea
WCB Working Cell Bank
USP United Stable Pharmacopeia
UV Ultraviolet Visible Spectroscopy
NCCN National Comprehensive Cancer Network
FOLFIRI Folinic Acid Fluorouracil and Irinotecan
FOLFOX Folinic Acid Fluorouracil and Oxaliplatin
IgG Immunoglobulin GBBS Basal Cell Carcinoma

Highlights

1. The names of the borders of the buccal and labial surfaces of all teeth are identical to those of the lingual surfaces.
2. To lubricate and comfort delicate throat tissues, a little piece of medicinal sweets that should melt slowly in the mouth is recommended.
3. A little, medicated candy that should melt gradually in the tongue to lubricate and soothe sensitive throat tissues.

4. The sixth most common type of cancer in the world is oral squamous cell carcinoma (OSCC).
5. Cetuximab was shown in phase III trials to have a greater response rate and a significant improvement

in OS when administered in combination with radiation in (LA HNSCC) and platinum-based chemotherapy in (R-M HNSCC).




Figure 7: Cetuximab oral trans mucosal lollipop.